Company insight
Cold challenge: safeguard cell and gene therapies during clinical trials
In recent years, the pharmaceutical landscape has seen rapid advancements in the field of cell and gene therapies. While these innovative therapies offer promising and personalised treatments against various diseases, they also present distinctive logistical challenges as Thermo Fisher explains.
he delicate nature of cell and gene therapies cannot be overstated. Unlike traditional pharmaceutical drugs, these therapies are exceptionally sensitive and can lose their efficacy if not maintained within precise temperature ranges. Maintaining the stability of these therapies is not merely a matter of protocol but a critical factor that directly impacts the collection of accurate data regarding their safety and effectiveness. Even a minor deviation from the specified temperature parameters can have far-reaching consequences, potentially jeopardizing the therapeutic properties of the treatment and the integrity of ongoing clinical trials. The logistical complexities involved in handling and distributing these therapies amplify the obstacles already encountered in clinical trials. Unlike traditional mass- produced pharmaceuticals, cell and gene therapies are developed in small quantities, often customized for individual patients. This bespoke approach renders mass production and distribution impractical, adding an unprecedented layer of complexity to their manufacturing and distribution processes. Each small batch necessitates a meticulous end-to-end strategy, encompassing specialized, temperature-controlled protocols for storage, packaging, labeling, and distribution. Precision and organization are paramount, ensuring that every step is executed with utmost care to prevent any deviations in temperature. Additionally, these therapies are typically administered at the clinical trial site, necessitating seamless coordination among the manufacturing facility, trial site,
T 22
and logistics providers. This synchronization is essential to ensure timely delivery and administration, all while adhering to the stringent temperature requirements. When clinical trials are conducted on a global scale, the challenges multiply. One of the foremost challenges lies in the sheer size of the global supply network. The vast distances that therapies need to travel, often crossing multiple borders and climates, introduce inherent vulnerabilities. Delays in transportation are not uncommon, whether due to customs clearance processes, logistical bottlenecks, or geopolitical issues. These delays can lead to extended periods of exposure for the products, increasing the likelihood of temperature excursions and compromising the efficacy and safety of the materials. Moreover, navigating customs regulations and compliance requirements in different countries poses a significant hurdle. Each nation has its unique import and export regulations, and any discrepancies or misunderstandings in fulfilling these requirements can lead to products being held up in customs, further extending the time spent outside the recommended temperature range. Such delays are particularly detrimental in the context of the cell and gene therapies, where precise temperature control is paramount.
Innovations and Solutions In response to these challenges, researchers and manufacturers have embarked on a journey of innovation. They are constantly developing cutting-edge technologies to navigate the complexities inherent in cell
and gene therapy clinical trials. Researchers are actively exploring advanced cryopreservation techniques, incorporating novel cryoprotectants and freezing protocols. These efforts aim to enhance the stability and viability of cells and genetic materials during storage and transportation, ensuring that the product remains potent and effective until it reaches the patients. Manufacturers have embraced sustainable and reusable shipping solutions such as thermal packaging, equipped with state-of- the-art temperature sensors and real-time monitoring capabilities. These innovative technologies provide continuous, real-time data on the therapies' environmental conditions, enabling visibility throughout the entire journey. They can quickly detect minor deviations from specified temperature ranges, allowing stakeholders to swiftly identify and rectify any discrepancies. This continuous oversight ensures that the therapies maintain their potency and safety, guaranteeing their effectiveness when administered to patients.
These groundbreaking innovations underscore a united commitment within the pharmaceutical industry to proactively identify and mitigate potential vulnerabilities in the cold chain for cell and gene therapy clinical trials. This collective effort not only ensures the safety and effectiveness of these advanced therapies but also paves the way for transformative research, empowering patients to access life-changing treatments with unwavering confidence.●
www.thermofisher.com Clinical Trials Insight /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41
